Supplementary Material




Figure S1: 3CL^{pro} amino acid sequence and structure analysis. (A) A comparison of two 3CL^{pro} structures of SARS-CoV and SARS-CoV-2. 3CL^{pro} of SARS-CoV (2Z9J) was shown in blue, and 3CL^{pro} of SARS-CoV-2 (6LU7) was shown in red. (B) The 3CL^{pro} amino acid sequences of both SARS-Cov and SARS-CoV-2 were compared, and the polar amino acids were marked in blue. (C) Comparison of the 3CL^{pro} amino acid sequence of both SARS-Cov and SARS-CoV-2. Negatively charged amino acids were shown in red and positively charged amino acids are shown in red.




Figure S2: Three-dimensional binding modes of Cangrelor and Ceftolozane with 3CL^{pro}. (A and C) The three-dimensional binding modes of both Cangrelor and Ceftolozane with 3CL^{pro}, respectively Protein shown as a cartoon model and ligands shown as stick model. (B and D) The interaction modes of both Cangrelor and Ceftolozane with 3CL^{pro}, respectively.




Figure S3: Three-dimensional binding modes of Cobicistat and Indinavir with 3CL^{pro}. (A and C) The three-dimensional binding modes of both Cobicistat and Indinavir with 3CL^{pro}, respectively. Protein shown as a cartoon model and ligands shown as stick model. (B and D) The interaction modes of both Cobicistat and Indinavir with 3CL^{pro}, respectively.




Figure S4: Three-dimensional binding modes of Thymopentin and Telaprevir with 3CL^{pro}. (A and C) The three-dimensional binding modes of both Thymopentin and Telaprevir with 3CL^{pro}, respectively. Protein shown as a cartoon model and ligands shown as stick model. (B and D) The interaction modes of both Thymopentin and Telaprevir with 3CL^{pro}, respectively.




Figure S5: Analysis of Molecular Dynamics Simulation results of the free 3CL^{pro} and the 3CL^{pro}-drug complex. (A) Root Mean Square Deviation (RMSD) of the 3CL^{pro}-Thymopentin complex and the free 3CL^{pro}. (B) Intermolecular hydrogen

bonds between the Thymopentin and the 3CL^{pro}. (C) RMSD of the 3CL^{pro}-Cangrelor complex and the free 3CL^{pro}. (D) Intermolecular hydrogen bonds between the Cangrelor and 3CL^{pro}. (E) RMSD of the 3CL^{pro}-Ceftolozane complex and the free 3CL^{pro}. (F) Intermolecular hydrogen bonds between the Ceftolozane and 3CL^{pro}. (G) RMSD of the 3CL^{pro}-Cobicistat complex and the free 3CL^{pro}. (H) Intermolecular hydrogen bonds between the Cobicistat and 3CL^{pro}. (G) RMSD of the 3CL^{pro}-Indinavir complex and the free 3CL^{pro}. (H) Intermolecular hydrogen bonds between the Indinavir and 3CL^{pro}.

Movie 1: Molecular dynamics simulation of the docking complex of Viomycin and 3CL^{pro}. Surface represents 3CL^{pro}, and sticks represent Viomycin.

Movie 2: Molecular dynamics simulation of the docking complex of Capastat and 3CL^{pro}. Surface represents 3CL^{pro}, and sticks represent Ritonavir.

Movie 3: Molecular dynamics simulation of the docking complex of Ritonavir and 3CL^{pro}. Surface represents 3CL^{pro}, and sticks represent Ritonavir.

Movie 4: Molecular dynamics simulation of the docking complex of Lopinavir and 3CL^{pro}. Surface represents 3CL^{pro}, and sticks represent Lopinavir.

Movie 5: Molecular dynamics simulation of the docking complex of Carfilzomib and 3CL^{pro}. Surface represents 3CL^{pro}, and sticks represent Carfilzomib.

Movie 6: Molecular dynamics simulation of the docking complex of Saquinavir and 3CL^{pro}. Surface represents 3CL^{pro}, and sticks represent Saquinavir.